NovaBridge Biosciences (NBP) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nkarta (NKTX) has outperformed NovaBridge Biosciences (NBP) over the past year, gaining 6.2% versus a loss of 73.0%. Over five years, NKTX leads with a -87.9% price change compared with -97.9% for NBP. NovaBridge Biosciences is the larger company by market cap ($162.4 million vs $160.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBP | NKTX |
|---|---|---|
| Share price | $1.40 | $2.24 |
| Market cap | $162.40M | $160.08M |
| 1-day change | +2.19% | +0.68% |
| YTD return | -65.58% | +20.00% |
| 1-year return | -72.98% | +6.22% |
| 5-year return | -97.92% | -87.90% |
| EPS (TTM) | $-0.69 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.79 | $3.72 |
| 52-week low | $1.31 | $1.70 |
| Distance from 52-week high | -79.38% | -39.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +542.86% | +384.56% |
| Average volume | 382.99K | 613.16K |
| Shares outstanding | 116.00M | 71.62M |
| Employees | 30 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed NBP by 79.2 percentage points over the past year.
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
NBP vs NKTX FAQ
Which is bigger, NovaBridge Biosciences or Nkarta?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $162.40M compared with $160.08M for Nkarta (NKTX).
Which stock has performed better over the past year, NBP or NKTX?
NKTX returned +6.22% over the past 12 months, compared with -72.98% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are NovaBridge Biosciences and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.